VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

Lack of systemic absorption was observed with VALCHLOR1,2

VALCHLOR works only where applied for local activity without bloodstream absorption1,2

Blood samples were analyzed in the clinical trial program from 16 patients using VALCHLOR (mechlorethamine gel 0.016%) and 15 patients using an identical formulation consisting of mechlorethamine 0.032% w/w.1,2

  • No detectable plasma mechlorethamine concentrations in 0.016% group1
  • No measurable plasma mechlorethamine or half-mustard concentrations in the 0.032% group at 2, 4, or 6 months of treatment1
  • No drug interaction studies have been performed with VALCHLOR. Systemic exposure has not been observed with topical administration of VALCHLOR; therefore, systemic drug interactions are not likely1

Watch the video for highlights—lack of systemic absorption was observed with VALCHLOR in a subset of patients from the pivotal trial